MONEY

FDA Approves Genentech's Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy

Tomas Kauer - ModeratorTomas Kauer - Moderator
Sep 13, 2024 - 08:00
FDA Approves Genentech's Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy
Read More

Tags:

Previous Article

Marc Andreessen's funds sell over $14 million in Samsara stock

Next Article

Protagonist Therapeutics director Waddill sells $360,000 in stock

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Tomas Kauer - Moderator
Tomas Kauer - Moderator

Related Posts

Factbox-What are India's antitrust findings against Amazon, Flipkart

Factbox-What are India's antitrust findings against Ama...

Tomas Kauer - Mode... Sep 14, 2024

Silvercorp to buy back 4% of shares in new repurchase program

Silvercorp to buy back 4% of shares in new repurchase p...

Tomas Kauer - Mode... Sep 17, 2024

Datadog stock price target reduced, keeps upbeat rating on strong first quarter

Datadog stock price target reduced, keeps upbeat rating...

Tomas Kauer - Mode... May 9, 2024